Republished news from European biotech media
Bispecific antibodies are gaining popularity for their dual-targeting ability, making them attractive to drug developers. Recent acquisitions by major pharma companies highlight this trend. Both new and established biotechs are advancing innovations in this field, with six standout companies featured in the article.
AP Biosciences is pioneering bispecific antibody therapies for cancer. Its lead candidates, AP505 and AP203, target immune checkpoints and tumor microenvironments to enhance T cell responses while minimizing systemic toxicity. AP505, in phase 1 trials, blocks PD-L1 and VEGF to boost immune activity and inhibit tumors. AP203, in phase 1/2a trials, engages CD137 and PD-L1 to activate T cells. Supported by its Omni-Mab and T-cube platform, the company raised $38M in Series D funding in June 2024.
The news content is cited from Labiotech.eu.
